Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
US9938268B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9938268-B2 |
| Application number | US-200913140090-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 2, 2009 |
| Priority date | Dec 17, 2008 |
| Publication date | Apr 10, 2018 |
| Grant date | Apr 10, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 4-Fluoro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-2-trifluoromethyl-1-benzamide; 2,3-Difluoro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; 3, 4-Difluoro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; 3, 5-Difluoro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; 4-Fluoro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; 2-Fluoro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-3-trifluoromethyl-benzamide; 3, 5-Dichloro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; 2,6-Dichloro-N-[4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; 3-Fluoro-N-[3-fluoro-4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-2-benzamide; 4-Fluoro-N-[2-fluoro-4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-2-trifluoromethyl-benzamide; 3, 4-Difluoro-N-[3-fluoro-4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide; and 2, 3-Difluoro-N-[3-fluoro-4-(6-oxo-5,6,7,8,9,10-hexahydrobenzo[c][1,8]naphthyridin-1-ylamino)-phenyl]-1-benzamide. 2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or any mixture thereof, and a pharmaceutically acceptable carrier, excipient, adjuvant and/or diluent.
Drugs for immunological or allergic disorders · CPC title
Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antineoplastic agents · CPC title
Immunomodulators · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.